PFE Pfizer, a darling of the Covid pandemic era is currently down from 56$
Pfizer emerged as a significant beneficiary during the Covid-19 era, witnessing a surge in its stock price. However, as the Covid-19 concern recedes, its share price has also returned most of its gains. Nevertheless, Pfizer's success isn't solely dependent on a single event, as it possesses a diverse portfolio of drugs that contribute to a more varied revenue stream. Although the Covid-19 vaccines brought substantial profits to Pfizer, its resilience lies in its broader pharmaceutical offerings. Morningstar has provided a fair valuation of $48, indicating a potential upside of 46%.
Conservatives target are at $36 - $42 still a massive upside opportunity
Pfizer emerged as a significant beneficiary during the Covid-19 era, witnessing a surge in its stock price. However, as the Covid-19 concern recedes, its share price has also returned most of its gains. Nevertheless, Pfizer's success isn't solely dependent on a single event, as it possesses a diverse portfolio of drugs that contribute to a more varied revenue stream. Although the Covid-19 vaccines brought substantial profits to Pfizer, its resilience lies in its broader pharmaceutical offerings. Morningstar has provided a fair valuation of $48, indicating a potential upside of 46%.
Conservatives target are at $36 - $42 still a massive upside opportunity
Publications connexes
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Publications connexes
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.